HAVCR2 and Miyoshi myopathy: In the multicohort, open-label, phase 1/2 MajesTEC-1 study, in which the safety/efficacy of teclistamab (a B cell maturation antigen (BCMA)-CD3 BsAb IgG4) were evaluated in patients with RR-MM, encouraging efficacy was demonstrated and indicated that a higher frequency of T cells expressed IC markers, including TIM-3, and this may be an underlying reason for non-responders observed with unfavorable immune characteristics at baseline [220].